CurePSP Strengthens Leadership with New Board Additions

CurePSP Strengthens Leadership with New Board Additions

CurePSP, the prominent nonprofit organization focused on research and advocacy for progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA), is embarking on an exciting chapter. Recently, the organization has welcomed two dynamic leaders, Stephen E. Canter and Salin Geevarghese, to its Board of Directors. Additionally, Kristophe Diaz, PhD, the former executive director and chief scientific officer, has received a well-deserved promotion to the role of chief executive officer.

A Vision for the Future

As CurePSP ventures into its next phase, the organization recognizes the importance of strong leadership. Board Chair, Jack Phillips, expressed confidence in the new appointments. "CurePSP is embarking on a period of unprecedented growth in research, care, advocacy, and awareness. The inclusion of Dr. Kristophe Diaz as CEO, alongside the insights of Steve Canter and Salin Geevarghese, is a critical move for our future endeavors. Their wealth of experience and unwavering commitment will help us advance our mission to eradicate PSP, CBD, and MSA," he stated.

Enhancing Our Mission

Diaz echoes this optimism, stating, "These strategic leadership additions invigorate our mission. Salin brings personal experience with CBD, and Stephen’s determination to foster growth in PSP research are crucial as we aim to boost our investments in corticobasal degeneration, while simultaneously driving progress in PSP and MSA." Under their combined leadership, CurePSP is committed to accelerating breakthroughs, broadening support for patients and caregivers, and paving the way for more efficient diagnoses and treatments.

Noteworthy Initiatives and Achievements

The recent leadership changes coincide with CurePSP's most successful fiscal year in its 35-year history. This period was highlighted by significant strides in raising awareness, community support, and efforts towards finding a cure for PSP, CBD, and MSA. Notable initiatives include:

• The PSP Trial Platform (PTP): A collaborative effort with the University of California, San Francisco, to develop a pioneering clinical trial platform capable of testing three PSP medications simultaneously.
• CurePSP Genetics Program: A nationwide program focused on in-home genetic sample collection to assist researchers in better comprehending and treating PSP, CBD, and MSA.
• Quality of Life Respite Care Fund: Provision of essential financial assistance to help families afford professional in-home care, significantly enhancing their quality of life.

Kristophe Diaz's promotion to CEO is a testament to these achievements, representing a larger strategy aimed at bolstering and amplifying the organization's leadership as it works to create a global impact in the neurodegenerative field.

A Personal Commitment to Change

Canter, who has joined the board in memory of his wife’s battle with PSP, shared, "My time on the Board is dedicated to the individuals living with PSP, their caregivers, and families. Serving in this capacity is a privilege that allows me to utilize my experiences to enhance our impact and drive positive change." On the other hand, Geevarghese, influenced by personal loss due to Alzheimer's and CBD, is committed to ensuring that the memories of his loved ones inspire significant progress in research and treatment.

Expertise Behind the Leadership

Stephen E. Canter brings a wealth of experience as a seasoned investment management executive. His career has included pivotal roles at leading global firms, and he currently serves as Managing Director at Zephyr Management, L.P. Canter’s dedication extends to several nonprofit organizations, having contributed to The John F. Kennedy Library Foundation. He holds an A.B. in Economics from Cornell University and an M.B.A. from Columbia University.

Salin Geevarghese is a lawyer known for his advocacy in equity and social inclusion. Currently, he acts as President & CEO of SGG Insight, LLC, an impact consulting firm. His previous experience includes a significant tenure in the Obama Administration, focusing on policies aimed at increasing access to opportunities across various sectors.

About CurePSP

CurePSP remains at the forefront of the fight against PSP, CBD, and MSA. The organization is dedicated to fostering awareness, improving care, and facilitating research aimed at discovering effective treatments and ultimately a cure. As a registered 501(c)(3) charity, it thrives on partnerships, funding vital research globally, and enhancing education and quality of life for those affected.

Frequently Asked Questions

What is CurePSP?

CurePSP is a nonprofit organization dedicated to raising awareness, improving care, and funding research for progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA).

Who has joined the board of CurePSP?

Stephen E. Canter and Salin Geevarghese have been welcomed to the CurePSP Board of Directors.

What is the role of Kristophe Diaz?

Kristophe Diaz has been promoted to the position of Chief Executive Officer of CurePSP, focusing on advancing research and advocacy efforts.

What initiatives has CurePSP launched recently?

Some recent initiatives include the PSP Trial Platform, CurePSP Genetics Program, and the Quality of Life Respite Care Fund to support families.

How does CurePSP impact the community?

CurePSP enhances education, care delivery, and provides support to improve the quality of life for individuals living with PSP, CBD, and MSA.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.